Abstract
N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Hypertensive Heart DiseasePatients with hypertensive heart disease have elevated concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The aim of our study was to evaluate NT-proBNP in patients with long-standing hypertension and in patients with signs of hypertensive cardiomyopathy. The study included three groups of 50 subjects: healthy persons (Control Group), patients with hypertension and normal left ventricular systolic function (Group 1) and patients with longstanding hypertension and signs of hyper tensive cardiomyopathy with impaired left ventricular systolic function (Group 2). Our results show a very good correlation (Pearson's test) between NT-proBNP in Group 1 and Group 2 and C-reactive protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856), diastolic blood pressure (Group 1: r = 0.4282; Group 2: r = 0.3989) and ejection fraction (Group 1: r = -0.7390; Group 2: r = 0.9111). ROC analysis revealed that the AUC between the Control Group and Group 1 for NT-proBNP (0.912) was not significantly different (p>0.05) from the AUC for systolic (0.924) and diastolic pressure (0.937). A cut-off value for NT-proBNP of 5.89 pmol/L can be used to reliably distinguish patients of Group 1 from the Control Group, and a cut-off value of 21.67 pmol/L reliably separates patients from Group 1 and Group 2 (in both cases, the AUC is 1.000). Patients in Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those in NYHA class I (ANOVA test, p=0.001). These data suggest that NT-proBNP is a useful biomarker for distin guishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients.
Highlights
Kratak sadraj: Pacijenti sa hipertenzivnim sr~anim oboljenjima imaju povi{ene koncentracije N-terminalnog pro-Btipa natriuretskog peptida (NT-proBNP)
These data suggest that NT-proBNP is a useful biomarker for distinguishing patients with long-standing hypertension who are at risk of heart failure, allowing optimization and proper treatment of these patients
Patients from Group 2 who belonged to the II and III New York Heart Association (NYHA) class had significantly higher levels of NT-proBNP than those with NYHA class I (ANOVA test, p = 0.001)
Summary
Kratak sadraj: Pacijenti sa hipertenzivnim sr~anim oboljenjima imaju povi{ene koncentracije N-terminalnog pro-Btipa natriuretskog peptida (NT-proBNP). Cilj rada bio je da se izvr{i evaluacija razlika u NT-proBNP kod pacijenata sa dugogodi{njom arterijskom hipertenzijom i znacima hipertenzivne kardiomiopatije. ROC analiza je pokazala da se AUC izme u kontrolne grupe i grupe 1 za NT-proBNP (0,912) zna~ajno ne razlikuje (p > 0,05) od AUC za sistolni (0,924) i dijastolni pritisak (0,937). Na osnovu cutoff vrednosti za NT-proBNP od 5,89 pmol/L mogu se pouzdano razlikovati pacijenti u grupi 1 od kontrolne grupe, dok se pomo}u cutoff vrednosti od 21,67 pmol/L pouzdano razdvajaju pacijente iz grupe 1 i grupe 2 (u oba slu~aja AUC su 1,000). Pacijenti u grupi 2 koji su pripadali II i III New York Heart Association (NYHA) klasi su imali zna~ajno vi{e vrednosti NT-proBNP od onih u I
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call